How Cardio-Oncology is called to prove its maturity

During the first years of its life, Cardio-Oncology, born ‘only’ to detect and treat events of cardiotoxicity, experienced a significant change of its own nature. Cardio-oncologists are nowadays called to face multiple, different and complex issues: to evaluate the cardiovascular (CV) profile of a cancer patient prior starting anticancer treatments; to estimate the risk of cardiotoxicity; how to adequately manage this eventuality, in some cases evenwithout halting the causative therapy;whether to suggest a cardiologic follow up at the end of the treatment.